Jazz Pharmaceuticals plc (JAZZ)

Jazz Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
Revenue	4,439	4,268	4,069	3,834
Revenue Growth (YoY)	9.20%	4.88%	6.12%	-
Cost of Revenue	532.78	503.3	445.71	435.58
Gross Profit	3,906	3,764	3,623	3,399
Selling, General & Admin	1,648	1,809	1,385	1,343
Depreciation & Amortization Expenses	672.51	654.66	627.31	608.28
Research & Development	1,746	1,731	894	868.66
Other Operating Expenses	122.8	-	-	-
Total Operating Expenses	4,189	4,195	2,907	2,820
Operating Income	-283.35	-430.24	716.63	578.58
Total Non-Operating Income (Expense)	-181.1	-197.62	-246.28	-280.65
Pretax Income	-218.85	-627.86	470.35	297.93
Provision for Income Taxes	-248.53	-272.44	-91.43	-119.91
Net Income	29.49	-356.15	560.12	414.83
Net Income to Common	29.49	-356.15	560.12	414.83
Net Income Growth	-93.88%	-	35.02%	-
Shares Outstanding (Basic)	61	61	62	63
Shares Outstanding (Diluted)	63	61	66	72
Shares Change (YoY)	-1.16%	-7.61%	-8.41%	-
EPS (Basic)	0.46	-5.84	9.06	6.55
EPS (Diluted)	-0.02	-5.84	8.65	6.10
EPS Growth	-	-	41.80%	-
Shares Outstanding	61.56	61.44	60.63	62.26
Free Cash Flow	1,270	1,297	1,358	1,068
Free Cash Flow Growth	-2.11%	-4.48%	27.13%	-
Free Cash Flow Per Share	20.13	21.27	20.57	14.82
Gross Margin	88.00%	88.21%	89.05%	88.64%
Operating Margin	-6.38%	-10.08%	17.61%	15.09%
Profit Margin	0.66%	-8.35%	13.77%	10.82%
FCF Margin	28.60%	30.39%	33.37%	27.86%
EBITDA	429.48	266.06	1,377	1,217
EBITDA Margin	9.68%	6.23%	33.83%	31.75%
EBIT	-283.35	-430.24	716.63	578.58
EBIT Margin	-6.38%	-10.08%	17.61%	15.09%
Effective Tax Rate	113.56%	43.39%	-19.44%	-40.25%

Updated May 5, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q